Compare Travere Therapeutics Inc. Common Stock (TVTX) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs United States Natural Gas Fund — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while United States Natural Gas Fund trades at $11.17 (market cap $503.45M). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 9.7× United States Natural Gas Fund's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and United States Natural Gas Fund for 23 Days on average.
| TVTX | UNG | |
|---|---|---|
Market Cap | $4.88B | $503.45M |
Volume | 1,668,577 | 27,352,527 |
Sector | Health | Commodities - Energy |
52-Week High | $67.52 | $16.90 |
52-Week Low | $26.79 | $9.63 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $5.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
UNG trades at $11.41, up 4.49% today, with a bullish technical signal from moving averages. The fund shows strong net income of $65.15M for 2024 despite zero revenue, supported by $593.54M in cash. Recent news highlights natural gas market volatility, with record U.S. production and geopolitical tensions influencing prices.
Outlook: Bullish technicals and solid liquidity offer upside, but reliance on natural gas price swings and zero revenue pose risks. Investors should weigh energy market stability against the fund's cash position and income generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
